Browsing Tag
TSX Venture Exchange
59 posts
Kraken Robotics nearly tripled its revenue target, but one margin number changes the story
Kraken Robotics Inc. (TSXV: PNG) added C$135 million to its 2026 revenue-guidance midpoint after including Covelya, while acquisition financing increased its share base and lowered the implied adjusted EBITDA margin.
Boardwalktech reports fiscal 2026 revenue drop as AI platform build-out completes
Boardwalktech's FY26 revenue fell 25% to $3.6 million as cash thinned to $140 thousand, with the completed AI platform now facing a decisive FY27 test.
Graphite One’s Ohio move looks small, but the battery supply chain signal is much bigger
Find out how Graphite One’s Ohio battery materials contract could reshape U.S. graphite supply chain ambitions and investor sentiment.
Elcora’s South African gold mine deal adds optionality, but Eldorado still needs technical proof
Elcora has a South African gold option. The real test is whether Eldorado’s tailings and geology can move from promise to proof.
Can DeepGreenX turn Green Panda Capital’s TSX-V shell into a real-world asset finance play?
Green Panda gives DeepGreenX a TSX-V route after its Nasdaq reset. See why this RTO tests tokenized asset finance.
Sarama Resources Q1 results sharpen focus on SRR cash runway and Australia exploration strategy
Sarama Resources cut losses, but cash fell below US$300,000. The next test is whether SRR can fund its Australia-led exploration pivot.
How Benton Resources Inc. and Metals Creek Resources Corp. are building a Newfoundland helium and natural hydrogen land strategy
Find out how Benton Resources and Metals Creek are expanding Newfoundland’s helium and natural hydrogen strategy in the Deer Lake Basin.
Vector Science & Therapeutics (TSXV: PAIN) targets intratumoral pancreatic cancer drug delivery with new microneedle catheter patent
Pancreatic cancer needs better local therapy. Vector Science & Therapeutics is betting its patent strategy can open a new delivery path.
Sabio FY25 results show ad-tech reset as SBIO trades near 52-week low
Sabio lost the election-year boost, but programmatic and international revenue may reset the SBIO story. Read how the 2026 test is shaping up.
Hydreight Technologies turns profitable as VSDHOne reshapes the NURS stock growth story
Hydreight has growth and profit, but platform scale brings scrutiny. Read why VSDHOne is now central to the NURS stock story.